Where does Hangzhou Adamerck Pharmlabs, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Hangzhou Adamerck Pharmlabs, Inc. ranks #47,307 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Hangzhou Adamerck Pharmlabs, Inc. hold?

Hangzhou Adamerck Pharmlabs, Inc. holds 5 US utility patents granted between 2015 and 2024, spanning 7 technology areas.

What is Hangzhou Adamerck Pharmlabs, Inc.'s Innovation Score?

Hangzhou Adamerck Pharmlabs, Inc. has an Innovation Score of 28.2 out of 100 (26th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Hangzhou Adamerck Pharmlabs, Inc. focus on?

Hangzhou Adamerck Pharmlabs, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 5 patents, ranking #3,434 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Hangzhou Adamerck Pharmlabs, Inc.'s patent grant rate increasing or decreasing?

Hangzhou Adamerck Pharmlabs, Inc.'s recent grant velocity is -33% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Hangzhou Adamerck Pharmlabs, Inc.'s patents?

Hangzhou Adamerck Pharmlabs, Inc.'s patents average 10.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Hangzhou Adamerck Pharmlabs, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Hangzhou Adamerck Pharmlabs, Inc.

USPTO PatentsView assignee record - 5 granted patents across 7 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Hangzhou ranks #47,307 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 7 technology areas.

#47,307
of 49,997 US assignees by volume: 26th percentile
by Innovation Score (28.2/100): 10.0
avg claims per patent: -33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R47307 · Foreign Corporation #47,307 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #47,307/49,997
PHOTO-FINISH Hammelmann
CPC-NARROW A61P · 7 areas
INNOV-THIN 28.2/100
CLAIMS-PAR 10.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Hammelmann GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Hangzhou’s 28.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (22%) Velocity 6.7 pts (24%) Breadth 9.4 pts (33%) Claim depth 6.0 pts (21%)

Qualcomm Incorporated · highest

85
Claussen Technology · near

28
Hangzhou Adamerck… · this assignee

28
Quantapore · near

28
SignalFox · near

28
Manaflex · near

28
3D Lighting… · lowest

7

What this shows Hangzhou's Innovation Score is 28.2/100 (26th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Hangzhou?

Each dot is one of Hangzhou’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Hangzhou’s own 10.0 claims/patent is ABOVE the 4.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Hangzhou vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Hangzhou's grants concentrate

Hangzhou Adamerck Pharmlabs, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). By volume, Hangzhou sits between Hammelmann GmbH and Hanning Elektro-Werke GmbH & Co. KG.

Hangzhou's three-year grant acceleration

Hangzhou Adamerck Pharmlabs, Inc. shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Hammelmann

5
Hammerhead Group

5
Handbag Heidi

5
Handle Financial

5
Hangzhou Leibo In…

5
Hangzhou Tanlink…

5
Hangzhou Yameilij…

5
Hanning Elektro-w…

5
Hangzhou Adamerck… ◀

5

What this shows Hangzhou holds 5 patents at rank #47,453, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Hangzhou

By rank, the assignees closest to #47,453 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Hangzhou's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Hangzhou, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Hangzhou ranks #3,434 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (28 here).

Quantapore, Inc. 28 SignalFox, Inc. 28 Claussen Technology, LLC 28 Manaflex, LLC 28

Hangzhou's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 26th percentile higher than 26% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Hangzhou Adamerck Pharmlabs, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	20.0%
2016	1	20.0%
2018	1	20.0%
2020	1	20.0%
2024	1	20.0%

Which technologies does Hangzhou Adamerck Pharmlabs, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C08B - POLYSACCHARIDES; Derivatives Thereof 2

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 2

A23V - Indexing Scheme Relating TO Foods, Foodstuffs OR Non-alcoholic Beverages AND Lactic OR Propionic Acid Bacteria Used IN Foodstuffs OR Food Preparation 2

C07D - Heterocyclic Compounds 1

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Hangzhou Adamerck Pharmlabs, Inc.'s patent record in context - here's where to go next.

Hangzhou Adamerck Pharmlabs, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #47,307 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Hangzhou Adamerck Pharmlabs, Inc. against Hammelmann GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.